Adaptimmune Therapeutics (NASDAQ:ADAP) just reported results for the fourth quarter of 2023.
- Adaptimmune Therapeutics reported earnings per share of -24 cents. This was below the analyst estimate for EPS of -10 cents.
- The company reported revenue of $231,000.
- This was 98.87% worse than the analyst estimate for revenue of $20.47 million.